04 jan: Fransk præsidentkandidat vil erstatte euroen med ecu-system
04 jan: A&O får godkendelse til køb af egne aktier fra storaktionær
04-01-2017 14:26:34

Bavarian Nordic Provides Update on Anticipated Timing of PROSPECT Study

Relateret indhold
05 dec - 
Aktier/åbning: Vestas retter sig oven på brat nedtur
05 dec - 
Aktier/tendens: Novo ser frem mod spændende tirsdag
05 dec - 
NKT tilføjes til C25-indekset på bekostning af Sydbank ..
Relateret debat
09 dec - 
Som jeg rent faktisk skrev, Prostvac var ikke virknings..
09 dec - 
Tak for svar Leif. Som jeg ser det ud af dit svar er Pr..
09 dec - 
Der er, når det gælder studier af medicin, rigtig meget..

  • PROSTVAC® overall survival data anticipated in the second half of 2017

COPENHAGEN, Denmark, January 4, 2017 - Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) today provided guidance for the current estimated timing of interim and final overall survival analysis from the PROSPECT study - a placebo controlled Phase 3 study designed to investigate the efficacy of PROSTVAC to prolong the survival of men with metastatic castration-resistant prostate cancer (mCRPC).

The company maintains its previous guidance that full data is expected within this year, albeit in the second half of 2017, with the third interim analysis likely to occur around mid-2017. This estimate is based on a decline in the number of average monthly events currently seen in the PROSPECT study.

"As there has been speculation that the third interim could occur during first quarter of 2017, we believe it is important to update the market on the current estimated timelines for readout of the Phase 3 study" said Paul Chaplin, President and CEO of Bavarian Nordic.

While the company remains blinded to all patient specific data, the latest estimates have been provided by the independent Data Monitoring Committee (DMC) following a routine analysis of the current survival data.

"While we will have to await the final read out of the PROSPECT study to establish the efficacy of PROSTVAC, we are encouraged that the current monthly event rate has declined. This is great news for the patients. Not only is this consistent with an improvement in the standard of care for patients with mCRPC, which has been observed in recent years, but could also be indicative of a therapeutic effect of PROSTVAC as well" said Paul Chaplin.

About the PROSPECT study

PROSPECT is a global, randomized, double-blind, placebo-controlled phase 3 study being conducted under a Special Protocol Assessment (SPA) from the FDA. The objective of the study is to determine whether PROSTVAC alone or in combination with GM-CSF is effective in prolonging overall survival. The study has been fully enrolled with 1,297 asymptomatic or minimally symptomatic mCRPC patients as of January 2015. Patients were enrolled at more than 200 sites in 15 countries. Both the first and second interim analyses confirmed that the study would continue as planned. Final study data requires 534 events in both comparisons of treatment arms versus placebo, and the third interim analysis will occur at 427 events.

About PROSTVAC

PROSTVAC (rilimogene galvacirepvec/rilimogene glafolivec, or "rilimogene") is a prostate specific antigen (PSA)-targeted immunotherapy candidate designed to enhance or stimulate the body's immune response, specifically T cells that will home to and kill prostate cancer cells, altering the course of the disease and improving overall survival (OS) of patients with prostate cancer. A robust data package has been established that includes 18 ongoing or completed clinical studies, comprising more than 2,000 patients of which more than 1,100 patients have been actively treated with PROSTVAC, which has been generally well-tolerated. A randomized, placebo-controlled Phase 2 trial demonstrated the potential of PROSTVAC to extend the median overall survival by 8.5 months in patients with advanced prostate cancer. These results led to the initiation of the PROSPECT pivotal Phase 3 study.

PROSTVAC is being developed in collaboration with the National Cancer Institute under a Cooperative Research and Development Agreement.

About Bavarian Nordic

Bavarian Nordic is a fully integrated biotechnology company focused on the development, manufacturing and commercialization of cancer immunotherapies and vaccines for infectious diseases, based on the Company's live virus vaccine platform. Through long-standing collaborations, including a collaboration with the U.S. government, Bavarian Nordic has developed a portfolio of vaccines for infectious diseases, including the non-replicating smallpox vaccine, IMVAMUNE®, which is stockpiled for emergency use by the United States and other governments. The vaccine is approved in the European Union (under the trade name IMVANEX®) and in Canada. Bavarian Nordic and its partner Janssen are developing an Ebola vaccine regimen, which has been fast-tracked, with the backing of worldwide health authorities, and a vaccine for the prevention and treatment of HPV. Additionally, in collaboration with the National Cancer Institute, Bavarian Nordic has developed a portfolio of active cancer immunotherapies, including PROSTVAC®, which is currently in Phase 3 clinical development for the treatment of advanced prostate cancer. The company has partnered with Bristol-Myers Squibb for the potential commercialization of PROSTVAC. For more information visit www.bavarian-nordic.com or follow us on Twitter @bavariannordic.

Forward-looking statements

This announcement includes forward-looking statements that involve risks, uncertainties and other factors, many of which are outside of our control, that could cause actual results to differ materially from the results discussed in the forward-looking statements. Forward-looking statements include statements concerning our plans, objectives, goals, future events, performance and/or other information that is not historical information. All such forward-looking statements are expressly qualified by these cautionary statements and any other cautionary statements which may accompany the forward-looking statements. We undertake no obligation to publicly update or revise forward-looking statements to reflect subsequent events or circumstances after the date made, except as required by law.

Contacts

Rolf Sass Sørensen

Vice President Investor Relations (EU)

Tel: +45 61 77 47 43

Seth Lewis

Vice President Investor Relations (US)

Tel: +1 978 341 5271

Company Announcement no. 02 / 2017

2017-02-en


This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.

The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: Bavarian Nordic A/S via Globenewswire

Vedhæftet fil: 2017-02-en.pdf

Opret kommentar

Relateret debat

  • 1 uge
  • 1 måned
  • 1 År
09 dec
BAVA
Der er, når det gælder studier af medicin, rigtig meget der fejler, og det er altid umuligt på forhå..
11
06 dec
BAVA
Jeg reduceret kraftig ifm kikset med fase 3 prostvac og har gået og fuld med i kursudvikling samt me..
9
05 dec
BAVA
Ja og bunden på dine RTX ser også dybere og dybere ud. Du har tabt styrtende i år. Sørgelige mennesk..
7
07 dec
BAVA
KVISTGÅRD: “Ny vaccinefabrik gør Bavarian Nordic uafhængig af underleverandører”. Det er ugeavisen I..
6
07 dec
BAVA
Måske de har noget at producere vi ikke kender til endnu :p 
4
05 dec
BAVA
Baronen   Kunne du ikke anlægge en helt ny stil og bare opføre dig som en 16 årig og ikke som en 8 å..
4
09 dec
BAVA
Som jeg rent faktisk skrev, Prostvac var ikke virkningsløs. Prostvac havde formentlig (Vi har ikke d..
3
08 dec
BAVA
Jeg skal have købt, venter lige og ser tiden an i næste uge..vil gerne have dem til 220-225. 
2
08 dec
BAVA
Jeg købte 400 forleden, ikke baseret på en masse analyser, men kun min egen holdning til selskabets ..
1
08 dec
BAVA
BAVA er nu den eneste aktie jeg har i porten, der ikke er aktiefonde og indeks.   Har kigget på pric..
1

Aktier/middag: Bankerne holder C20 Cap i positivt terræn

11-12-2017 11:18:26
Med god understøttelse fra bankpapirerne holder de danske aktier netop snuden over vandet mandag formiddag, hvor der ellers er flest elitepapirer med tilbagegang.C20 Cap-indekset stiger ved 11.15-tiden med 0,1 pct. til 1126,98.Bankpapirerne trækker læsset i toppen, og her er det stadig de nye Basel-krav, der er den afgørende katalysator. Stramningerne af kapitalkravene fra komitéen er tilsyneladen..

Aktier/tendens: Mærsk og Genmab i fokus i roligt mandagsmarked

11-12-2017 08:15:18
Rekorder på Wall Street og gode takter på børserne i Asien kombineret med svagt positive futurespriser tyder på en positiv åbning på det danske aktiemarked mandag, hvor Mærsk og Genmab kan løbe med opmærksomheden.Det amerikanske S&P 500-indeks steg yderligere en smule efter dansk børslukketid fredag. De amerikanske futures ligger desuden en anelse højere mandag morgen, mens den tyske DAX-futures l..

Mest læste nyheder

  • 24 timer
  • 48 timer
  • 1 uge
1
Aktier/tendens: Mærsk og Genmab i fokus i roligt mandagsmarked
2
Investeringsdirektør: Aktiepriserne bør få alarmlamperne til at blinke
3
Bitcoin fortsætter kursridt efter debut på børs i USA
4
Genmab-rival suser frem på børsen efter nyt kræftstudie
5
TK Development tager markant nedskrivning og venter stort underskud

Relaterede aktiekurser

Bavarian Nordic A/S 233,50 -0,2% Fald i aktiekurs

Køb- og salgsanbefalinger

  • Trend
  • Pengemaskinen

Copyright Euroinvestor A/S 2017  Disclaimer Privatlivspolitik
Aktieinformation leveres af Morningstar.
Data er forsinket 15-20 minutter iht. de enkelte børsers regler om videredistribution.
 
11. december 2017 16:12:32
(UTC+01:00) Brussels, Copenhagen, Madrid, Paris
Version: LiveBranchBuild_20171124.1 - EUROWEB5 - 2017-12-11 16:12:32 - 2017-12-11 16:12:32 - 1 - Website: OKAY